

1 **Supplementary Information**

2

3 **Actomyosin contractility drives apical polarization**
4 **and membrane transport during tubulogenesis**

5

6


Yuji Mizotani^{1*}, and Edwin M. Munro^{1*}

7 ¹ Department of Molecular Genetics and Cell Biology, University of Chicago; Chicago, IL 60637,
8 USA.

9

*Corresponding authors: ymizotani@uchicago.edu; emunro@uchicago.edu


10



11


12 **Supplementary Fig. 1. Rho Kinase is required for both lumen initiation and growth**
 13 **(related to Fig. 1).** a–f Quantitative analysis of notochord morphology in embryos treated either
 14 with vehicle control (DMSO) or with 10 μM H1152 starting from 13 hpf (a–c) or 15 hpf (d–f),
 15 fixed at 18 hpf and stained with Alexa 488 Phalloidin to label F-actin. (a, d) Representative
 16 micrographs; (b, e) measurements of lumen volume; (c, f) measurements of notochord AP cell
 17 length. Scale bars: 5 μm . Horizontal bars in (b), (c), (e), (f) show mean \pm SEM (Welch’s t-test).
 18 NS, not significant; *P < 0.001.

19



20


21 **Supplementary Fig. 2. Lateral actomyosin is required for polarization of Par3 and Par6**
 22 **(related to Fig. 2).** **a** Representative micrographs showing sagittal and transverse views of
 23 notochord cells expressing mNG:Par3 (top) or mNG:Par6 (bottom), before (13 hpf) and after (15
 24 hpf) treatment with vehicle control (DMSO) or pAB. Dashed rectangles indicate axial positions
 25 used for transverse views. **b** Quantification of the signal intensities along lateral cell contacts for
 26 the indicated treatments. Faint thin lines indicate measurements on individual contacts; thick
 27 lines show the average. **c** Boxplots show peak signal intensities on individual contacts for the
 28 indicated treatments. Horizontal lines indicate median, + indicate mean, boxes indicate second
 29 and third quartiles, and whiskers indicate 95% confidence interval. Scale bars: 5 μ m. Mann-
 30 Whitney U test with Bonferroni's correction; NS, not significant; * $P < 0.001$.



31


32 **Supplementary Fig. 3. BI 2536 is a basal selective inhibitor of actomyosin that does not**
 33 **inhibit apical polarization (related to Fig. 2).** **a** Representative images (left) and quantification
 34 of successful division rates (right) in embryos treated with the indicated concentrations of BI
 35 2536 up to ~ 1 hpf, when embryos normally complete first cleavage. **b, c** Representative
 36 micrographs (**b**, left) and quantification of basal and lateral 1P-myosin staining (**b**, right) and AP
 37 cell length (**c**) in embryos treated with vehicle control (DMSO) and BI 2536 from 13–15 hpf. **d**
 38 Representative micrographs of notochord cells expressing mNG:Par3, mNG:Par6, or aPKC at 15
 39 hpf after the treatment with vehicle control (DMSO) or BI 2536 from 13–15 hpf. Dashed
 40 rectangles indicate axial positions used for transverse views. **e** Quantification of the signal
 41 intensities along lateral cell contacts for the indicated treatments. Faint thin lines indicate
 42 measurements on individual contacts; thick lines show the average. **f** Boxplots show peak signal
 43 intensities on individual contacts for the indicated treatments. Horizontal lines indicate median, +
 44 indicate mean, boxes indicate second and third quartiles, and whiskers indicate 95% confidence
 45 interval. In dot plots, data are mean \pm SEM. Welch's t-test with Bonferroni's correction for (**a**);
 46 Mann-Whitney U test for (**b**), (**c**), and (**f**); NS, not significant; *P < 0.05, **P < 0.001.

47



48


49 **Supplementary Fig. 4. BI 2536 is a basal selective inhibitor of actomyosin that inhibits**
50 **lumen formation and cell elongation without affecting lumen opening along lateral axis**
51 **(related to Fig. 3). a, b** Representative micrographs (a) and quantification of basal and lateral
52 1P-myosin staining (b) in 16.5 hpf embryos treated with vehicle control (DMSO), BI 2536, or
53 H1152 from 15 hpf. Pink dashed lines indicate the positions of lumens. **c–e** Representative
54 micrographs (c) and quantification of lateral lumen opening (d) and AP cell length (e) in 16 hpf
55 phalloidin-stained embryos, treated with vehicle control (DMSO) and UTKO1 from 15–16 hpf.
56 **f–h** Representative micrographs (f) and quantification of lumen volume (g) and AP cell length
57 (h) in 18 hpf phalloidin-stained embryos, treated with vehicle control (DMSO) and UTKO1 from
58 15–18 hpf. **i** Summary of the notochord cell phenotypes caused by the treatment with pAB,
59 H1152, UTKO1, and BI 2536. Figure numbers and letters indicate the corresponding data. Scale
60 bars: 10 μm. In boxplots, horizontal lines indicate median, + indicate mean, boxes indicate
61 second and third quartiles, and whiskers indicate 95% confidence interval. In dot plots, data are
62 mean ± SEM. Mann-Whitney U test with Bonferroni's correction for (b); Welch's t-test with
63 Bonferroni's correction for (d), (e), (g), and (h); NS, not significant; *P < 0.001.



64


65 **Supplementary Fig. 5. Actomyosin moves inward to cytoplasm and moves toward the**
 66 **apical domain (related to Fig. 4).** **a** Representative sagittal and transverse sections (top left),
 67 and corresponding schematic views (bottom left), and kymographs (right) of a notochord cell
 68 expressing Lifeact:mNG. J = Lateral junction, L = lumen, A = apical and B = basal. Blue and
 69 orange rectangles indicate the regions used to construct the kymographs. Yellow arrowheads
 70 indicate detached sections of basal actin rings undergoing internalization. **b** Live images of cells
 71 expressing Lifeact:mNG immobilized by paralyzer MS-222, shown in sagittal and transverse
 72 sections. Yellow arrowheads indicate detached sections of actin rings undergoing internalization.
 73 **c** Live images of cells expressing Utrophin: Halo, and labelled with JF549. Yellow arrowheads
 74 indicate detached sections of basal actin rings undergoing internalization. **d** Micrographs of F-
 75 actin in fixed embryos stained with Alexa 488 Phalloidin, shown in sagittal and transverse
 76 sections. Yellow arrowheads indicate detached sections of basal actin rings undergoing
 77 internalization. **e** Basal myosin filaments showing local cortical tearing, followed by rapid lateral
 78 retraction of myosin, which remains associated with the basal surface (green arrowheads). **f** A 16

79 hpf embryo stained with FM4-64 to label membranes. Yellow arrowheads indicate internalizing
80 membrane. Scale bars in all images: 5 μ m.
81



82


83 **Supplementary Fig. 6. Basal actomyosin inhibition suppresses local detachment and**
 84 **inward movement of basal cortex and adjacent membranes (related to Fig. 4).** **a** Basal
 85 cortical view (top) and corresponding kymograph (bottom) of a 16 hpf notochord cell, expressing
 86 Halo:MRLC, and treated with pAB from 15 hpf. A = anterior, P = posterior. Dashed yellow box
 87 indicates the region used for the kymograph. **b** Representative micrographs (left) and
 88 corresponding kymograph (right) of notochord cells expressing markers for F-actin
 89 (Lifeact:mNG, top, green), plasma membrane (pm:mSc-I, middle, magenta), and their merge
 90 (bottom). Dashed yellow boxes indicate the regions used for the kymographs. **c, d** Quantification
 91 of speed (**c**) and frequency (**d**) of actomyosin movement from the basal cortex to cytoplasm. In
 92 boxplots, horizontal lines indicate median, + indicate mean, boxes indicate second and third
 93 quartiles, and whiskers indicate 95% confidence interval. Mann-Whitney U test: NS, not
 94 significant; * $P < 0.001$.



95

96 **Supplementary Fig. 7. ERM promotes both basal activation of myosin II and cortex-**
 97 **membrane linkage to direct internalization and directed movement of basal membranes**
 98 **toward the apical lumen surface (related to Fig. 5). a, b** Representative micrographs (a, left)
 99 and quantification of basal and lateral 1P-myosin staining (b, middle) and AP cell length (b) in
 100 15 hpf embryos after microinjection of eggs with control or ERM MO. **c** Representative
 101 micrographs (top), and measurements of lateral (bottom left) and peak (bottom right) signal
 102 intensities for notochord cells expressing mNG:Par3 at 15 hpf after microinjection of eggs with
 103 control or ERM MO. **d** Dynamics of Lifeact:mNG in 16 hpf embryos viewed in sagittal (left) or
 104 transverse (right) sections after injecting eggs with ERM MO. Green arrowheads indicate
 105 detached and internalized sections of the basal contractile ring; magenta arrowheads indicate
 106 outward displacement of the basal membrane just after local detachment of the actin ring from
 107 the basal surface. **e** Representative images (left), magnified snapshots (middle) and kymographs
 108 (right) from a 16 hpf embryo, expressing markers for F-actin (Lifeact:mSG (mStayGold)) and
 109 plasma membrane (pm:mSc-I) from an egg microinjected with a control morpholino. Yellow
 110 rectangles at left indicate regions used for magnified snapshots and kymographs. Yellow
 111 arrowheads indicate the movement of actin and membrane from the basal to apical domain. In

112 boxplots, horizontal lines indicate median, + indicate mean, boxes indicate second and third
113 quartiles, and whiskers indicate 95% confidence interval. Mann-Whitney U test: NS, not
114 significant; *P < 0.001.



115

116 **Supplementary Fig. 8. Anchorage to basal ECM promotes the normal cycle of cortical**
 117 **detachment and internalization of basal membranes (Related to Fig. 5)** **a, b** Representative
 118 micrographs **(a)** and quantification of basal and lateral 1P-myosin staining **(b)** at 16 hpf in
 119 embryos treated with (+) or without (-) Collagenase and Dispase (Coll+Disp). **c** Quantification of
 120 concavity index in embryos treated with (+) or without (-) Coll+Disp. Bottom schematic: The
 121 concavity index is defined to be the ratio of basal surface lengths, measured in sagittal cross
 122 sections, for muscle and notochord membranes. **d** Live images of cells expressing Lifeact:mSG
 123 (mStayGold), at the indicated timepoints (min), treated with Coll+Disp, shown in sagittal and
 124 transverse section. Green arrowheads indicate detached and internalized sections of the basal
 125 contractile ring; magenta arrowheads indicate outward displacement of the basal surface just
 126 after local detachment of the actin ring from the basal surface. **e** Representative images (left),
 127 and kymographs (right) from a 16 hpf embryo, expressing Halo:MRLC, and treated with
 128 Coll+Disp from 15 hpf. Dashed yellow box indicates the region used for the kymographs, and
 129 magenta arrowheads indicate repeated cycles of detachment and bleb-like protrusion. In
 130 boxplots, horizontal lines indicate median, + indicate mean, boxes indicate second and third
 131 quartiles, and whiskers indicate 95% confidence interval. Mann-Whitney U test: NS, not
 132 significant; * $P < 0.001$.

133

134 **Supplementary Movie 1** (Related to Fig. 4a). Dynamics of Lifeact:mNG (actin) and
135 Halo:MRLC (myosin II) in a control embryo at 16–17 hpf shown in sagittal and transverse
136 views. Time compression = 300x.

137 **Supplementary Movie 2** (Related to Supplementary Fig. 5a). Dynamics of Lifeact:mNG (actin)
138 in a control embryo at 16–17 hpf shown in sagittal and transverse views. Time compression =
139 300x.

140 **Supplementary Movie 3** (Related to Supplementary Fig. 5b). Dynamics of Lifeact:mNG (actin)
141 in an embryo at 16–17 hpf paralyzed with MS-222, shown in sagittal and transverse views. Time
142 compression = 300x.

143 **Supplementary Movie 4** (Related to Supplementary Fig. 5c). Dynamics of Utrophin:Halo
144 (actin) in an embryo at 16–17 hpf stained with JF549, shown in sagittal view Time compression
145 = 300x.

146 **Supplementary Movie 5** (Related to Fig. 4b–d). Dynamics of Halo:MRLC (myosin II) in a
147 control embryo at 16–17 hpf, shown in the basal cortex (left) and transverse view (middle), along
148 with the kymograph for basal cortex (right). Time compression = 300x.

149 **Supplementary Movie 6** (Related to Fig. 4e). Dynamics of Lifeact:mNG (actin) and pm:mSc-I
150 (membrane) in a control embryo at 16–17 hpf shown in sagittal view. Time compression = 300x.

151 **Supplementary Movie 7** (Related to Supplementary Fig. 5e). Dynamics of membrane
152 internalization, visualized by FM4-64, in a control embryo at 16–17 hpf shown in sagittal view.
153 Time compression = 300x.

154 **Supplementary Movie 8** (Related to Supplementary Fig. 6a). Dynamics of Halo:MRLC
155 (myosin II) on the basal cortex in an embryo treated with pAB 16–17 hpf shown in basal cortex
156 view. Time compression = 300x.

157 **Supplementary Movie 9** (Related to Fig. 4f). Dynamics of Lifeact:mNG (actin) and pm:mSc-I
158 (membrane) in an embryo treated with pAB at 16–17 hpf shown in sagittal view. Time
159 compression = 300x.

160 **Supplementary Movie 10** (Related to Fig. 4g). Dynamics of Lifeact:mNG (actin) and pm:mSc-I
161 (membrane) in an embryo treated with UTKO1 at 16–17 hpf shown in sagittal view. Time
162 compression = 300x.

163 **Supplementary Movie 11** (Related to Supplementary Fig. 6b). Dynamics of Lifeact:mNG
164 (actin) and pm:mSc-I (membrane) in an embryo treated with BI 2536 at 16–17 hpf shown in
165 sagittal view. Time compression = 300x.

166 **Supplementary Movie 12** (Related to Fig. 5b). Dynamics of Lifeact:mNG (actin) and pm:mSc-I
167 (membrane) in an embryo injected with ERM MO 16–17 hpf shown in sagittal view. Time
168 compression = 300x.

169 **Supplementary Movie 13** (Related to Supplementary Fig. 7e). Dynamics of Lifeact:mNG
170 (actin) and pm:mSc-I (membrane) in an embryo injected with control MO 16–17 hpf shown in
171 sagittal view. Time compression = 300x.

172 **Supplementary Movie 14** (Related to Supplementary Fig. 7d). Dynamics of Lifeact:mNG
173 (actin) in an embryo injected with ERM MO at 16–17 hpf shown in sagittal and transverse view.
174 Time compression = 300x.

175 **Supplementary Movie 15** (Related to Fig. 5h). Dynamics of Lifeact:mNG (actin) and pm:mSc-I
176 (membrane) in an embryo treated with Coll+Disp at 16–17 hpf shown in sagittal and transverse
177 view. Time compression = 300x.

178 **Supplementary Movie 16** (Related to Supplementary Fig. 8d). Dynamics of Lifeact:mNG
179 (actin) in an embryo treated with Coll+Disp at 16–17 hpf shown in sagittal and transverse view.
180 Time compression = 300x.

181 **Supplementary Movie 17** (Related to Supplementary Fig. 8e). Dynamics of Halo:MRLC
182 (myosin II) in an embryo treated with Coll+Disp at 16–17 hpf shown in sagittal and transverse
183 view. Time compression = 300x